Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer: The Roadmap to a Cure
Maria E. Cabanillas(The University of Texas MD Anderson Cancer Center), Mark Zafereo(Texas Medical Center), Renata Ferrarotto(The University of Texas MD Anderson Cancer Center), Priyanka Iyer(The University of Texas MD Anderson Cancer Center), Neal S. Akhave(The University of Texas MD Anderson Cancer Center), Victoria Banuchi(The University of Texas MD Anderson Cancer Center), Matthew S. Ning(The University of Texas MD Anderson Cancer Center), Naifa L. Busaidy(The University of Texas MD Anderson Cancer Center), Jennifer Wang(The University of Texas MD Anderson Cancer Center), Anastasios Maniakas(The University of Texas MD Anderson Cancer Center), Michelle D. Williams(The University of Texas MD Anderson Cancer Center), S. Mohsen Hosseini(University of Toronto), Ramona Dadu(The University of Texas MD Anderson Cancer Center), Stephen Y. Lai(The University of Texas MD Anderson Cancer Center), Michael T. Spiotto(The University of Texas MD Anderson Cancer Center), Marie‐Claude Hofmann(The University of Texas MD Anderson Cancer Center), Anna Lee(The University of Texas MD Anderson Cancer Center), Sarah Hamidi(The University of Texas MD Anderson Cancer Center)
Cited by 5
Related Papers
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
|Thyroid|2021|699
Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test
|Genetics in Medicine|2017|563